Skip to main content

University Hospitals Offers the Following Cell Therapy Clinical Trials

May 2018

CASE2Z16: Phase I Trial of Universal Donor NK Cell Therapy in Combination With ALT803
P.I.: Folashade Otegbeye, MD #NCT02890758

CASE2417: AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Non Hodgkin Lymphoma
P.I.: Paolo Caimi, MD #NCT03434769

CASE 1Z14: Intra-Osseous Co-Transplant of Cord Blood and Mesenchymal Stomal Cells: A Feasibility Study
P.I.: Leland Metheny, MD #NCT02181478

CASE 6307: O6-benzylguanine (BG) and Temozolomide (TMZ) Therapy of Glioblastoma Multiforme (GBM) in Patients with MGMT Positive Tumors with Infusion of Autologous P140KMGMT+Hematopoietic Progenitors to Protect Hematopoiesis
P.I.: Stan Gerson, MD #NCT01269424

CASE 3113: Pilot Trial of a Type I-Polarized Autologous Dendritic Cell Vaccine Incorporating Tumor Blood Vessel Antigen-Derived Peptides in Patients with Metastatic Breast Cancer
P.I.: Joseph Baar, MD #NCT02479230

BMT CTN 1401: Personalized DC vaccine for multiple myeloma
P.I.: Ehsan Malek, MD Identifier: NCT02728102


For more information about clinical trials taking place at UH Seidman Cancer Center contact Marcos de Lima, MD at